scholarly journals The rarity of gonococcal arthritis in association with HIV infection

2014 ◽  
Vol 8 (09) ◽  
pp. 1222-1227 ◽  
Author(s):  
Rasha Maharaj ◽  
Girish M Mody
Keyword(s):  
Neisseria Gonorrhoeae ◽  
Hiv Infection ◽  
Skin Rash ◽  
Throat Swab ◽  
Hiv Positive ◽  
Hiv Patients ◽  
Acute Arthritis ◽  
Gonococcal Urethritis ◽  
The Right

Gonococcal urethritis is common with HIV, but gonococcal arthritis is rare. We report two HIV-positive patients with gonococcal arthritis and review previously published reports. A 27-year-old HIV-positive female presented with a pustular skin rash and acute oligoarthritis. Neisseria gonorrhoeae was cultured from the right elbow aspirate. The second patient, a 24-year-old HIV-positive female on zidovudine for one month, presented at 28 weeks gestation with acute oligoarthritis and peroneal tenosynovitis. Neisseria gonorrhoeae was cultured from the throat swab. Both patients responded to ceftriaxone. Gonococcal arthritis must be considered in HIV patients with acute arthritis.

Lack of Medical Support in HIV Infection and Unstable Mood States

1997 ◽  
Vol 81 (2) ◽  
pp. 635-639
Author(s):  
Motoko Hayashi ◽  
Isao Fukunishi
Keyword(s):  
Social Support ◽  
Depressive Symptoms ◽  
Major Depression ◽  
Hiv Infection ◽  
Mood Disorders ◽  
Early Stage ◽  
Mood States ◽  
Hiv Positive ◽  
Medical Support ◽  
Hiv Patients

This study examined what kinds of social support are related to mood states in a sample of 50 HIV-positive patients without AIDS (46 men and 4 women; M age 36.5 yr., SD = 9.8). In the early stage of HIV infection, HIV patients without AIDS may be prone to depressive symptoms although none of these HIV-positive patients' symptoms fulfilled the DSM-III-R Mood Disorders including Major Depression. The depressive symptoms were not significantly related to lack of ordinary social support such as friends and family but were significantly associated with dissatisfaction with HIV/AIDS-related medical support

scholarly journals Preliminary report of HIV and Toxoplasma gondii occurrence in pregnant women from Mozambique

2010 ◽  
Vol 52 (6) ◽  
pp. 291-295 ◽  
Author(s):  
Sonia Paula Benedito Luis Sitoe ◽  
Bernardete Rafael ◽  
Luciana Regina Meireles ◽  
Heitor Franco de Andrade Jr. ◽  
Ricardo Thompson
Keyword(s):  
Hiv Infection ◽  
Pregnant Women ◽  
Severe Disease ◽  
Age Groups ◽  
Hiv Positive ◽  
High Avidity ◽  
Lower Prevalence ◽  
Serum Samples ◽  
African Countries ◽  
Hiv Patients

Toxoplasmosis, a protozoan disease, causes severe disease in fetuses during pregnancy and deadly encephalitis in HIV patients. There are several studies on its seroprevalence around the world, but studies focusing on African countries are limited in number and mostly anecdotal. We studied two groups of samples from Mozambique by ELISA, using serum samples from 150 pregnant women and six Cerebrospinal fluid (CSF) samples from AIDS patients with encephalitis. HIV status was confirmed, and CD4 blood counts were obtained from HIV-positive pregnant women. IgG seroprevalence of the group as a whole was 18.7% (28/150), with a higher prevalence in HIV-positive individuals compared to those who were HIV-negative (31.3%, [18/58] vs. 10.9%, [10/92]) patients. These data may be biased due to cumulative effects of exposition affecting disease prevalence. If corrected, this data may indicate an interaction of HIV and T. gondii. Prevalence of both diseases increases with age, but this is more clearly seen for toxoplasmosis (p < 0.005) than HIV infection, possibly explained by higher transmission of HIV after childhood. In HIV patients suffering from encephalitis, CSF serology showed that 33% of specific IgG CSF had a high avidity, which was in accordance with the data from the group of pregnant women. Lower prevalence rates of both infections in older groups could be explained by more deaths in the infected groups, resulting in an artificially lower prevalence. Using CD4 counts as a marker of time of HIV infection, and correcting for age, patients with contact with T. gondii had fewer CD4 cells, suggesting prolonged HIV disease or other causes. Toxoplasma IgG prevalence is higher in HIV+ groups, which could be ascribed to HIV- and T. gondii-associated risk factors, such as exposure to higher and more diverse social contacts. The low incidence of Toxoplasma IgG in younger age groups shows that transmission could be related to better access to cyst-containing meat in adulthood, as environmental transmission due to oocysts is usually blamed for higher incidence in children. Taken together, these data support the urgent need of research in toxoplasmosis in Africa, especially in the presence of HIV epidemics.

scholarly journals Clinicopathologic Comparison of Plasmablastic Lymphoma in HIV-Positive Versus HIV-Negative Patients: Single-Center Experience

Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 1864-1864 ◽  
Author(s):  
Jule Vasquez ◽  
Jorge Huamanchumo ◽  
Shirley Quintana
Keyword(s):  
Overall Survival ◽  
Hiv Infection ◽  
B Cell ◽  
Conflicts Of Interest ◽  
Plasmablastic Lymphoma ◽  
Aggressive Lymphoma ◽  
Cancer Center ◽  
Hiv Positive ◽  
Hiv Patients ◽  
Hiv Negative

Abstract Background: Plasmablastic lymphoma (PBL) is an aggressive lymphoma associated mainly to HIV infection, although cases in immunocompetent patients are described as well. Objective: To describe the prevalence, the clinicopathologic features and determine the overall survival of lymphoma patients according human immunodeficiency virus (HIV) status. Methods: We reviewed the pathology database at Instituto Nacional de Enfermedades Neoplasicas (INEN), the leading cancer center of Peru from 2005 to 2014. 6218 cases were lymphomas, 5031 cases were Non-Hodgkin lymphoma and 3905 cases were B-cell lineage. 22 met diagnosis of PBL, 4 patients were excluded (1 prior treatment, 1 synchronous malignancy and 2 incomplete medical records). Finally, we had 18 cases for evaluation. Survival curves were estimated by Kaplan Meier. Statistical analysis was based on SPSS Program version 22. Results: The prevalence of PBL was 0.004% of all Non-Hodgkin lymphomas and 0.005% of B-cell lymphomas. 13 of 18 cases (72.2%) were HIV-positive patients (PBL-HIV+). The median age for PBL-HIV+ was 37 years (range 22-67 years) and 58 years (range 53-74 years) for HIV-negative patients (PBL-HIV-).The extra-oral primary was the most frequent primary site in both groups. The advanced stage was 80% in PBL-HIV- patients. Presence of B-symptoms and Ki-67>80% were greater in PBL-HIV- patients. CHOP or CHOP-like regimen was the common treatment in both groups, only one patient received DA-EPOCH (PBL-HIV+ group). HAART-naïve patients were 77%. The median OS time was 43 months (range 1-84 months) in PBL-HIV+ patients and 13 months (range 0-15 months) in PBL-VIH- patients, the 5-yrs-OS was 26.9% y 0% respectively. Conclusions: Plasmablastic lymphoma is a rare lymphoma, either associated or not to HIV infection. Advanced and aggressive disease is a distinctive feature in both lymphomas. The PBL-HIV- has a worse prognosis with shorter overall survival compared to the PBL-HIV+ patients. Disclosures No relevant conflicts of interest to declare.

Clinicopathologic Comparison of Plasmablastic Lymphoma Patients According HIV-Status: Peruvian Experience

Blood ◽  
2020 ◽  
Vol 136 (Supplement 1) ◽  
pp. 19-19
Author(s):  
Jule F Vasquez ◽  
Cesar Samanez-Figari ◽  
Lourdes Lopez ◽  
Shirley Quintana ◽  
Rolig Aliaga ◽  
...  
Keyword(s):  
Overall Survival ◽  
Hiv Infection ◽  
Lymphoid Cells ◽  
Categorical Variables ◽  
Hiv Positive ◽  
Hiv Status ◽  
Hiv Patients ◽  
Variable Expression ◽  
Significant Difference ◽  
Hiv Negative

Background:Plasmablastic lymphoma (PBL) is an aggressive lymphoma associated mainly to HIV infection, although cases in immunocompetent patients are described as well. Objective:To describe the clinicopathologic features and determine the overall survival of lymphoma patients according human immunodeficiency virus (HIV) status in Peruvian patients. Methods:We reviewed the pathology databases of 2 cancer centers and a general hospital from Peru. Forty cases were documented between 2005 and 2020. Categorical variables were compared using Fisher's exact test. Survival curves were estimated using the Kaplan-Meier method and compared using the log-rank test. Statistical analysis was based on SPSS Program version 23. All cases were reviewed by two pathologists. Results:32 patients (80%) were HIV-positive. The median age for the whole cohort was 40 years (range, 22-86). The median age for HIV-positive and HIV-negative PBL patients were 37 years (range 22-67 years) and 57 years (range 27-86 years), respectively. The proportion of patients ≥60 years was lower in HIV-positive than in HIV-negative patients (8% and 37%, respectively; p= 0.046). 80% of patients in the whole cohort were female, and 84% and 62% in the HIV-positive and HIV-negative group, respectively. Extra-oral primary sites were the most frequent primary sites in both groups (66% and 88%, respectively). There were no statistically significant differences in Ann Arbor stage, Ki-67 expression, LDH levels, IPI scores, albumin levels, and neutrophil/lymphocyte ratio between HIV-positive and HIV-negative patients. All cases showed large lymphoid cells, of plasmablastic morphology with expression of at least one plasma cell marker (CD138, CD38, MUM1), CD45 positivity, variable expression of EMA, CD79 and CD30 and absence of expression of CD20, CD3, CD68 and LMP1; the proliferative index Ki67 varied between 60 and 90%. A small proportion of patients (18%) did not receive chemotherapy because of poor performance status or a personal decision. DA-EPOCH regimen was used in 52% and 25% of HIV+ and HIV- patients, respectively and CHOP/CHOEP regimen in 48 % and 75%, respectively. The overall response rate was 68% and 57% in HIV+ and HIV- patients with complete response (CR) in 32% and 14%, respectively. In the HIV-positive group, 66% of patients were antiretroviral therapy (ART)-naïve. The median progression-free survival (PFS) was 38 months and 7 months for HIV+ and HIV- patients, and the 1-year PFS was 74% and 0%, respectively. The median overall survival (OS) was 43 months (range 0.2-86.5) in HIV-positive patients and 10 months (range 0.5-19.0 months) in HIV-negative patients and the 1-year OS were 59% y 38%, respectively (p=0.27). Conclusions: PBL is a rare lymphoma, specially, if not related to HIV infection. In this study, 60 years or older was the only variable that showed significant difference. In our cohort, HIV-positive patients had better prognosis than HIV-negative PBL patients. Disclosures No relevant conflicts of interest to declare.

scholarly journals Knowledge, attitude and stigma towards HIV patients: a survey among medical students in Tuzla, Bosnia and Herzegovina

2020 ◽  
Vol 14 (09) ◽  
pp. 1019-1026
Author(s):  
Rahima Jahić ◽  
Humera Porobić-Jahić ◽  
Denis Žepić ◽  
Dilista Piljić ◽  
Jasminka Petrović ◽  
...  
Keyword(s):  
Medical Students ◽  
Hiv Infection ◽  
Bosnia And Herzegovina ◽  
Positive Attitude ◽  
Multivariate Regression Analysis ◽  
Hiv Positive ◽  
Hiv Education ◽  
Hiv Patients ◽  
Potential Risk Factors ◽  
Fourth Year Medical Students

Introduction: This survey aims to assess knowledge, attitude and stigma towards HIV patients, among medical students in Tuzla, Bosnia and Herzegovina. We also aimed to assess potential risk factors for HIV infection among fourth year medical students. Methodology: Data were collected from specific questionnaire that was completed by 171 students of the Faculty of Medicine, University of Tuzla. A multivariable logistic regression was performed. Results: Majority of students (79%) had a good knowledge of HIV, (median value of correct answers was 9 (95%) with at least 6 correct responses). Also, majority of students (73.6%) had a positive attitude towards HIV patients and the median positive value was 6 (95% CI: 6-7). More than a third of students considered that all hospitalized patients should be tested for HIV. Total of 81% of students considered that they should inform the sexual partner of HIV positive patient, although she/he disagrees. 61.4% of students had a discriminatory attitude towards HIV, with the median values of 3 (95% CI: 3-3). Multivariate regression analysis identified positive attitude towards HIV patients as an independent predictor for a non-discriminatory attitude. Moreover, an overall attitude towards HIV patients defines student`s determination to work with AIDS population. Male gender, and older age, were identified as predictors of risky behavior. Conclusions: Preventive measures, including better HIV education, are crucial. Knowledge can increase awareness of HIV infection, decrease the incidence and reduce stigma towards HIV patients.

HIV Status Does Not Impact on Outcome in Patients with Hodgkin Lymphoma Treated with ABVD Chemotherapy in the HAART Era,

Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 3646-3646
Author(s):  
Silvia Montoto ◽  
Kate Shaw ◽  
Jessica Okosun ◽  
Shreyans Gandhi ◽  
Paul Fields ◽  
...  
Keyword(s):  
Hiv Infection ◽  
Hodgkin Lymphoma ◽  
Prognostic Score ◽  
Hiv Positive ◽  
Hiv Status ◽  
University Hospitals ◽  
Hiv Viral Load ◽  
Hiv Patients ◽  
Abvd Chemotherapy

Abstract Abstract 3646 Background: The prognosis of patients with HIV and non-Hodgkin lymphoma (NHL) has improved considerably since the advent of HAART, approaching that of patients with NHL in the general population when treated with the same chemotherapy regimens. However, it is not clear whether the same holds true for patients with Hodgkin lymphoma (HL). Aim: To analyze the outcome of patients diagnosed with HL treated with ABVD in the HAART era according to HIV status. Patients: From 1997 to 2010, 237 patients (92 with HIV infection) were newly diagnosed with HL at 5 university hospitals in London and consecutively treated with ABVD chemotherapy. Patients with HIV were older (median age: 41 years vs 31, p<0.001) and more were men (88% vs 59%, p<0.001). The histology subtype was more frequently mixed cellularity in HIV patients (54%) than in non-HIV (19%, p<0.001). In addition, HIV positive patients had more advanced stage at diagnosis (stage III-IV: 80% vs 33%, p<0.001), B-symptoms (81% vs 36%, p<0.001), lower Hb level (<10.5g/dL: 46% vs 20%, p<0.001) and lower albumin level (<4g/dL: 76% vs 35%, p<0.001). Patients with HIV infection had more frequently high risk disease according to the International Prognostic Score than HIV negative patients (IPS>3: 71% vs 22%, p<0.001). Amongst HIV patients, the HIV viral load (VL) was undetectable at the time of HL diagnosis in 52 of 86 patients with available data. The median VL for the remainder was 4,563 (range: 3,060–6,066). Forty-seven patients (53%) had a CD4 count <200/mL. All patients were treated with 4–6 cycles of ABVD chemotherapy with or without radiotherapy to residual/bulky areas according to local policies. Ninety patients with HIV infection received HAART concomitantly during chemotherapy. Results: The complete response (CR) rate in HIV positive and negative patients was 74% and 81%, respectively (p=NS). Fifty-one patients (21%) received consolidation radiotherapy. After a median follow-up of 59 months (range: 8–172 months), 40 patients relapsed at a median time of 7 months (range: 1–106). The median duration of response for HIV positive and negative patients was 33 months and 48 months, respectively (p=NS). Thirty-three patients have died: in 25 cases of HL; 2 patients due to toxicity and 5 patients due to other causes. Five-year event-free survival (EFS) was 59% (95%CI: 46–69) for HIV patients and 65% (95%CI: 56–72) for the remainder (p=NS). Five-year overall survival (OS) was 79% (95%CI: 67–87) and 88% (95%CI: 80–92) for HIV positive and negative patients respectively (p=0.06). HIV status did not predict OS or EFS on multivariate analysis including all variables comprising the IPS and HIV status. Conclusions: This long follow-up study demonstrates that patients diagnosed with HL in the setting of HIV infection have a more extensive disease with adverse prognostic factors. However, when treated with ABVD chemotherapy HIV positive status does not adversely affect OS or EFS. Disclosures: Montoto: Roche: Honoraria; Genentech: Research Funding. Orkin:Janssen: Honoraria; Gilead: Honoraria; BMS: Honoraria; BI: Honoraria; MSD: Honoraria; GSK: Honoraria; Viiv: Honoraria. Gribben:Roche: Honoraria; Celgene: Honoraria; GSK: Honoraria; Mundipharma: Honoraria; Gilead: Honoraria; Pharmacyclics: Honoraria.

Alexithymic Characteristics of HIV-Positive Patients

1999 ◽  
Vol 85 (3) ◽  
pp. 963-970 ◽  
Author(s):  
Isao Fukunishi ◽  
Naotsugu Hirabayashi ◽  
Tomoko Matsumoto ◽  
Kyoko Yamanaka ◽  
Katsuyuki Fukutake
Keyword(s):  
Social Support ◽  
Hiv Infection ◽  
Stress And Coping ◽  
Psychiatric Research ◽  
Hiv Positive ◽  
Healthy Controls ◽  
Hiv Patients ◽  
Related Factors ◽  
The Social ◽  
And Coping

Despite extensive psychiatric research on HIV-positive patients, there are no published studies on alexithymia. Alexithymic characteristics and related factors were examined in a sample of 81 HIV-positive patients using the modified Beth Israel Psychosomatic Questionnaire and the Social Support of Stress and Coping Inventory. The seventy of alexithymia was significantly higher in HIV patients than healthy controls, suggesting the presence of secondary alexithymia Scores on two alexithymic characteristics, affect awareness and operational thinking, significantly correlated with ratings of poor utilization and perception of social support. As the severity of HIV infection progressed, affect awareness was higher, controlling for poor utilization and perception of social support. These results suggest that secondary alexithymia, associated with poor utilization and perception of social support, may be manifest as a state reaction to approaching death.

scholarly journals Clinical signs of tuberculosis relapses in HIV patients

2020 ◽  
Vol 98 (6) ◽  
pp. 32-35
Author(s):  
E. Yu. Zorkаltsevа ◽  
Yu. O. Egorovа
Keyword(s):  
Central Nervous System ◽  
Hiv Infection ◽  
Treatment Efficacy ◽  
Medical Records ◽  
Clinical Signs ◽  
Clinical Manifestations ◽  
Hiv Positive ◽  
Hiv Patients ◽  
The Central Nervous System ◽  
Hiv Negative

The objective: to study clinical manifestations of tuberculosis relapses and their treatment outcomes in patients with HIV infection.Subjects and Methods. 132 medical records of patients with tuberculosis relapses were analyzed; 69 of them were HIV-positive and 63 were HIV-negative. All of them were admitted to Irkutsk Regional Clinical Tuberculosis Hospital from 2016 to 2019, and then continued treatment of tuberculosis on the out-patient basis. Treatment efficacy was assessed in February 2020.Results. More severe clinical forms of tuberculosis relapses were typical of HIV patients including generalized forms affecting the central nervous system. Therefore, among these patients, the mortality rate is significantly higher (24.6%) than in tuberculosis relapses with no concurrent HIV infection (6.3%), p ≤ 0.05.

scholarly journals Pattern of hepatobiliary involvement in HIV/AIDS patients: study in a tertiary care centre

2018 ◽  
Vol 7 (1) ◽  
pp. 146
Author(s):  
Kamlesh Sharma ◽  
Vandana Sharma ◽  
Aradhana Singh ◽  
Ketki .
Keyword(s):  
Liver Disease ◽  
Liver Function ◽  
Hiv Infection ◽  
Tertiary Care ◽  
Liver Function Tests ◽  
Hiv Positive ◽  
Tertiary Care Centre ◽  
Hiv Patients ◽  
Function Tests ◽  
Hiv Test

Background: Diseases of hepatobiliary system is a major problem in patients with HIV infection. It has been estimated that approximately one third of the death of patients with HIV infection are in some way related to liver disease. While this is predominantly a reflection of the problems encountered in the setting of co-infection Hepatitis B or C, it is also a reflection of the hepatic injury in the form of hepatic steatosis, that can be due to antiretroviral therapy. There had been little work done on liver function tests in HIV patients without pre-existing liver disease like viral hepatitis, or alcoholic hepatitis. So, this study was designed to assess the pattern of liver function test derangement in HIV patients. Aims and objective was to study the different pattern of hepatobiliary involvement in HIV positive patients, and to gauge the extent of liver damage.Methods: The study included 50 HIV positive patients coming to SMS hospital and Medical College, Jaipur, in medicine and HIV clinic of skin and VD department. Subjects having HIV test positive by ELISA, are included in this study. Other causes of liver function derangements were excluded from the study.Results: Maximum number of the patients were in the age group of 23-32 years. Out of 50 cases studied, 41 (82 %) cases had abnormal liver function tests, while 9 (18%) had normal liver function tests. Most of the cases had liver function abnormalities, and most common abnormality was raised SGOT/SGPT.Conclusions: Almost all types of liver function tests are found to be deranged in HIV patients. The pattern of hepatobiliary involvement varied from fatty liver, cholestasis to Toxic necrosis and granulomas.

scholarly journals Seroprevalence of Human Cytomegalovirus Infection among HIV Patients in Khartoum State

2019 ◽  
Vol 4 (2) ◽  
pp. 1-4
Author(s):  
Mahjoob MO
Keyword(s):  
Hiv Infection ◽  
Human Cytomegalovirus ◽  
Opportunistic Infections ◽  
Hiv Positive ◽  
High Morbidity ◽  
Hiv Replication ◽  
Hiv Patients ◽  
Human Cytomegalovirus Infection ◽  
Immunodeficiency Syndrome ◽  
Hiv Seropositive

Background: Human Cytomegalovirus (HCMV) is one of the opportunistic infections associated with significantly high morbidity and mortality among patients living with immunodeficiency syndrome. CMV has been reported to enhance HIV replication and accelerate the progre ssion of HIV infection to AIDS. Aim: The aim of this study was to determine the prevalence of HCMV among HIV patients in Khartoum State, Sudan, during the period April to July 2018. Methods: The study was carried out in Khartoum State, Sudan. A total of 9 2 HIV sero - positive cases were included. HCMV IgG and IgM antibodies were detected using Enzyme Linked Immune Sorbent Assay. Results: Among 92 HIV positive samples, 91 (99%) were found positive for HCMV - IgG while 3 samples (3.2%) were positive for HCMV - I gM. Conclusion: In Sudan, the existence of HCMV in patients with HIV infection was confirmed by using ELISA. These findings indicate that CMV is hyper-endemic in HIV seropositive patients in Khartoum, Sudan.

Sign in / Sign up

Export Citation Format

Share Document